PMID- 38188474
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240109
IS  - 1927-1220 (Electronic)
IS  - 1927-1212 (Print)
IS  - 1927-1212 (Linking)
VI  - 12
IP  - 6
DP  - 2023 Dec
TI  - Haploidentical and Matched Sibling Transplantation for Acute Myeloid Leukemia: A 
      Hospital-Based Study.
PG  - 255-267
LID - 10.14740/jh1162 [doi]
AB  - BACKGROUND: Allogeneic peripheral blood stem cell transplantation (PBSCT) has 
      been increasing for the last years in Latin America. The objective of this study 
      was to describe clinical outcomes in acute myeloid leukemia (AML) receiving 
      allogeneic PBSCT between 2013 and 2019 in a single center of Cali, Colombia. 
      METHODS: A retrospective cohort study was conducted in Fundacion Valle del Lili. 
      Patients diagnosed with AML who received an allogeneic PBSCT between 2013 and 
      2019 using human leukocyte antigen (HLA)-matched sibling donors (MSDs) or 
      haploidentical related donors (HRDs) with myeloablative conditioning regimen were 
      included. Cases with diagnosis of promyelocytic leukemia, myelodysplastic 
      syndrome-related AML and therapy-related AML were excluded. Data were obtained 
      directly from the hospital PBSCT database and clinical records. RESULTS: A total 
      of 50 patients were included (HRD, n = 32; MSD, n = 18). Sixty-two percent was in 
      the first complete remission (CR1) at the time of the transplant, of which 26% 
      were MSD and 74% were HRD. The European Group for Blood and Marrow 
      Transplantation (EBMT) risk score was: 44% vs. 50% low, 28% vs. 28% intermediate 
      and 28% vs. 22% high for MSD vs. HRD, respectively. Overall survival at 5 years 
      for MSD was 62% (95% confidence interval (CI): 31-83%) and 43% (95% CI: 25-60%) 
      for HRD. Event-free survival was 56% (95% CI: 26-78%) and 35.6% (95% CI: 18-53%), 
      respectively. Non-relapse mortality at day-100 was 6% (95% CI: 0.8-35%) and 20% 
      (95% CI: 9-39%). Relapse at5 years was 18% (95% CI: 4-58%) and 25% (95% CI: 
      10-52%). Overall mortality rate was 46%. The grade II-IV, III-IV acute 
      graft-versus-host disease and severe chronic graft-versus-host disease was 44%, 
      11% and 12% for MSD, and 43%, 9% and 0% for HRD. CONCLUSION: These results 
      underline that MSD remains the first donor choice for AML patients in CR1 when 
      available. HRDs are still our next option among alternative donors. It is 
      necessary to find strategies that have a positive impact on those outcomes that 
      markedly affect the quality of allogeneic PBSCT and the prognosis of patients. 
      Comparative, randomized, prospective studies with longer follow-up of 
      haploidentical allogeneic PBSCT with other donor types are required to definitely 
      establish its role among alternative donors.
CI  - Copyright 2023, Baena et al.
FAU - Baena, Juan C
AU  - Baena JC
AD  - Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia.
AD  - Hematology Service, Department of Internal Medicine, Fundacion Valle del Lili, 
      Cali, Colombia.
FAU - Rosales, Maria C
AU  - Rosales MC
AD  - Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia.
FAU - Estacio, Mayra
AU  - Estacio M
AD  - Centro de Investigaciones Clinicas (CIC), Fundacion Valle del Lili, Cali, 
      Colombia.
FAU - Hidalgo, Alejandra
AU  - Hidalgo A
AD  - Centro de Investigaciones Clinicas (CIC), Fundacion Valle del Lili, Cali, 
      Colombia.
FAU - Arrieta, Elizabeth
AU  - Arrieta E
AD  - Hematology Service, Department of Internal Medicine, Fundacion Valle del Lili, 
      Cali, Colombia.
AD  - Bone Marrow Transplant Unit, Fundacion Valle del Lili, Cali, Colombia.
FAU - Jaramillo, Francisco J
AU  - Jaramillo FJ
AD  - Hematology Service, Department of Internal Medicine, Fundacion Valle del Lili, 
      Cali, Colombia.
AD  - Bone Marrow Transplant Unit, Fundacion Valle del Lili, Cali, Colombia.
FAU - Manzi, Eliana
AU  - Manzi E
AD  - Centro de Investigaciones Clinicas (CIC), Fundacion Valle del Lili, Cali, 
      Colombia.
FAU - Parra-Lara, Luis Gabriel
AU  - Parra-Lara LG
AUID- ORCID: 0000-0002-4877-1117
AD  - Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia.
AD  - Centro de Investigaciones Clinicas (CIC), Fundacion Valle del Lili, Cali, 
      Colombia.
FAU - Rosales, Joaquin D
AU  - Rosales JD
AD  - Hematology Service, Department of Internal Medicine, Fundacion Valle del Lili, 
      Cali, Colombia.
AD  - Bone Marrow Transplant Unit, Fundacion Valle del Lili, Cali, Colombia.
LA  - eng
PT  - Journal Article
DEP - 20231228
PL  - Canada
TA  - J Hematol
JT  - Journal of hematology
JID - 101635099
PMC - PMC10769648
OTO - NOTNLM
OT  - Acute myeloid leukemia
OT  - Bone marrow transplantation
OT  - Colombia
OT  - Donors
OT  - Hematopoietic stem cell transplantation
OT  - Myeloablative conditioning regimen
OT  - Survival
COIS- None to declare.
EDAT- 2024/01/08 07:01
MHDA- 2024/01/08 07:02
PMCR- 2023/12/28
CRDT- 2024/01/08 05:13
PHST- 2023/07/07 00:00 [received]
PHST- 2023/11/17 00:00 [accepted]
PHST- 2024/01/08 07:02 [medline]
PHST- 2024/01/08 07:01 [pubmed]
PHST- 2024/01/08 05:13 [entrez]
PHST- 2023/12/28 00:00 [pmc-release]
AID - 10.14740/jh1162 [doi]
PST - ppublish
SO  - J Hematol. 2023 Dec;12(6):255-267. doi: 10.14740/jh1162. Epub 2023 Dec 28.